Log in Free sign up

Blueprint Medicines (BPMC) News and press releases

News

From Benzinga Pro

Guardant Health and Blueprint Medicines Presenting Real-world Data Identifying EGFR C797X Mutation as Most Common Resistance Mechanism to Osimertinib Therapy at IASLC 2022 World Conference on Lung Cancer

Guardant Health Inc.

Where Blueprint Medicines Stands With Analysts

Analyst Ratings

Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:

Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $143

News, Price Target, Analyst Ratings

Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $126 to $143.

SVB Leerink Maintains Market Perform on Blueprint Medicines, Raises Price Target to $65

News, Price Target, Analyst Ratings

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and raises the price target from $56 to $65.

Raymond James Maintains Strong Buy on Blueprint Medicines, Lowers Price Target to $115

News, Price Target, Analyst Ratings

Raymond James analyst Dane Leone maintains Blueprint Medicines (NASDAQ:BPMC) with a Strong Buy and lowers the price target from $133 to $115.

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Blueprint Medicines: Q2 Earnings Insights

Blueprint Medicines (NASDAQ:BPMC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Blueprint Medicines Q2 EPS $(2.68) Misses $(2.23) Estimate, Sales $36.55M Miss $37.24M Estimate

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(2.68) per share which missed the analyst consensus estimate of $(2.23) by 20.18 percent. This is a 44.09 percent decrease over losses of $(1.86) per share

Earnings Scheduled For August 2, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

A Preview Of Blueprint Medicines's Earnings

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-2.23.

3 Biotech Stock Picks From This Wedbush Analyst

Analyst Color, Biotech, Small Cap, Analyst Ratings, Trading Ideas, General

While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June.

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Oppenheimer Initiates Coverage On Blueprint Medicines with Outperform Rating, Announces Price Target of $80

News, Price Target, Initiation, Analyst Ratings

Oppenheimer analyst Matthew Biegler initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Outperform rating and announces Price Target of $80.

Benzinga Pro's Top 5 Stocks To Watch For Friday, Jul. 1, 2022: GM, KSS, NIO, RIOT, BPMC

Pre-Market Outlook

Today's 5 Stock Ideas: General Motors (GM) - A Bank Of America analyst on Thursday noted both GM and Ford (F) will have overtaken Tesla (TSLA) in the electric vehicle market by 2025. Kohl's (KSS) -

Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=890922

SVB Leerink Maintains Market Perform on Blueprint Medicines, Lowers Price Target to $56

News, Price Target, Analyst Ratings

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.

This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'

Analyst Color, Biotech, News, Health Care, Financing, Offerings, Analyst Ratings, General

Blueprint Medicines Announces Transformative $1.25B Strategic Financing Collaborations With Sixth Street And Royalty Pharma

Blueprint Medicines Corporation (NASDAQ:BPMC) today announced strategic financing collaborations with Sixth Street and Royalty Pharma (NASDAQ:RPRX) for up to $1.25 billion, bringing significant non-dilutive, low-cost

What 7 Analyst Ratings Have To Say About Blueprint Medicines

Analyst Ratings

Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Press releases

From Benzinga Pro

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 4, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

-- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

NEW YORK, July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Blueprint Medicines Corporation - BPMC

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 7, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

NEW YORK, July 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

M&A, News, Press Releases

Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma

Strengthens balance sheet with significant non-dilutive, low-cost capitalExpands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

News, Legal, Press Releases

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are advised to

Blueprint Medicines Appoints Habib Dable to its Board of Directors

CAMBRIDGE, Mass., June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

News, Legal, Press Releases

NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are advised to

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

News, Legal, Press Releases

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are advised to

Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis

-- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data for prior standard therapies, to be presented at EHA 2022 Congress

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced